Harmonized System
U.S. imports of Opacifying Preparations for X-Ray Examinations (HS 300630) totaled $147.4M in August 2026, imported from 21 countries.
Importers of Opacifying Preparations for X-Ray Examinations paid $94K in duties in August 2026, an average duty rate of 0.06% — duty actually collected as a share of the imports that cleared customs, not the published tariff schedule. Opacifying Preparations for X-Ray Examinations imports of $147.4M in August 2026 ran 31% above the year-to-date monthly average of $112.6M.
Last updated: August 2026 dataContrast media and diagnostic agents used to enhance visibility in radiological imaging fall under FDA oversight as drugs or medical devices, requiring compliance with applicable premarket approval or 510(k) clearance pathways before US entry. The US tariff schedule distinguishes preparations containing antigens or similar immunological components (3006301000) from other opacifying preparations (3006305000), a split that affects both classification and regulatory review. Germany and Norway are the leading suppliers, reflecting the concentration of advanced pharmaceutical manufacturing in Western Europe. Importers should verify that each shipment's formulation aligns with the correct 10-digit line, as misclassification between the antigen-containing and non-antigen lines is a recurring audit issue.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
346 import shipments a month
The schedule separates preparations containing antigens or similar immunological components (3006301000) from all other opacifying preparations (3006305000). The distinction turns on the product's active ingredient profile, so importers must review the formulation carefully — misclassification can trigger duty discrepancies and FDA admissibility complications.
Contrast agents are regulated as drugs or medical devices by FDA. Depending on the product, the importer must demonstrate either an approved New Drug Application (NDA), an Abbreviated NDA, or 510(k) clearance. Shipments from unapproved establishments or without valid marketing authorization are subject to refusal of admission. Consult a licensed customs broker or regulatory counsel to confirm admissibility requirements for a specific formulation.
Subheading 1 of 9 in heading 3006
Subheading 300630 · $147.4M of $357.1M
Trade Directory
List your company under HS 300630 — Opacifying Preparations for X-Ray Examinations, so the companies trading it can find you. Be the first supplier listed.
ImportsExports
Imports
$147.4MYoY · free account
Exports
$5.4MYoY · free account
12-mo low · imports
Low · free accountOver the twelve months to August 2026, the U.S. imported $1.2B of Opacifying Preparations for X-Ray Examinations and exported $78.3M.
Through August 2026. Source: U.S. Census Bureau.
HS10 import codes under this HS6 parent, each with its own page. Source: U.S. Harmonized Tariff Schedule.
| Code | Description | Imports for consumption | Average duty rate | Dutiable Share | Duty Collected |
|---|---|---|---|---|---|
| 3006305000 | Other Opacifying Preps for X-Ray Examinations Etc | $147.4M | 0.06% | 0.63% | $94K |
| 3006301000 | Opacifying Preparations Etc Cont Antigens Etc | — | -- | -- | -- |
HS10 export codes under this HS6 parent, each with its own page. Source: U.S. Schedule B export classification.
| Code | Description | Export Value |
|---|---|---|
| 3006300000 | Opacifying Preparations for X-Ray Examinations Etc | $5.4M |
Import lines come from the U.S. Harmonized Tariff Schedule and export lines from Schedule B. The two are numbered by different agencies, so the same 10-digit code can appear in both tables describing a different product.
Imports · August 2026
origin
Germany and Norway together supply 67% of it.
customs district
destination
entry
rate provision · imports
99.4% enters free of duty; duty collected equals 0.06% of imports for consumption.